Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the 32P-postlabeling technique

Biomedical Papers

Volumn 156, Issue 2, 2012, Pages 115-121

  Stiborova, Marie ^a   Poljakova, Jitka ^a   Eckschlager, Tomas ^b   Kizek, Rene ^c,d   Frei, Eva ^e  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c MENDEL UNIVERSITY IN BRNO   (Czech Republic)

^d BRNO UNIVERSITY OF TECHNOLOGY   (Czech Republic)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

32P postlabeling; Cancer; DNA adducts; Doxorubicin; Ellipticine; Neuroblastoma

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; ELLIPTICINE; ELLIPTICINE DERIVATIVE; PHOSPHORUS;

ARTICLE; DNA ADDUCT; HUMAN; ISOTOPE LABELING; METABOLISM; NEUROBLASTOMA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA ADDUCTS; DOXORUBICIN; ELLIPTICINES; HUMANS; ISOTOPE LABELING; NEUROBLASTOMA; PHOSPHORUS RADIOISOTOPES;

EID: 84864021138     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2012.043     Document Type: Article

References (38)

1. Maris JM, Mathay KK Molecular biology of neuroblastomas. J Clin Oncol 1999;17:2264-79.
2. Schwab M. Human neuroblastoma: from basic science to clinical debut of cellular oncogenes. Naturwissenschaften 1999;86:71-8.
3. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
4. Voigt A, Hartmann P, Zintl F. Differentiation, proliferation and adhesion of human neuroblastoma cells after treatment with retinoic acid. Cell Adhes Commun 2000;7:423-40.
5. Hopkins-Donaldson S, Yan P, Bourloud KB, Muhlethaler A, Bodmer JL, Gross N. Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells. Oncogene 2002;21:6132-7.
6. Morgenstern BZ, Krivoshik AP, Rodriguez V, Anderson PM. Wilms' tumor and neuroblastoma. Acta Paediatr Suppl 2004;93:78-85.
7. Poljakova J, Eckschlager T, Hrabeta J, Hrebackova J, Smutny S, Frei E, Martínek V, Kizek R, Stiborová M. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. Biochem Pharmacol 2009;77:1466-79.
8. Auclair C. Multimodal action of antitumor agents on DNA: The ellipticine series. Arch Biochem Biophys 1987;259:1-14.
9. Monnot M, Mauffret O, Simon V, Lescot E, Psaume B, Saucier JM, Charra M, Belehradek J Jr, Fermandjian S. DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J Biol Chem 1991;25:1820-9.
10. Fossé P, Rene B, Charra M, Paoletti C, Saucier JM. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationships. Mol Pharmacol 1992;42:590-5.
11. Froelich-Ammon SJ, Patchan MW, Osheroff N, Thompson RB. Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J Biol Chem 1995;270:14998-15004.
12. Stiborová M, Bieler CA, Wiessler M, Frei E. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol 2001;62:1675-84.
13. Stiborová M, Rupertová M, Schmeiser HH, Frei E. Molecular mechanism of antineoplastic action of an anticancer drug ellipticine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006;150:13-23.
14. Stiborová M, Rupertová M, Frei E. Cytochrome P450-and peroxidasemediated oxidation of anticancer alkaloid ellipticine dictates its antitumor efficiency. Biochim Biophys Acta 2011;1814:175-85.
15. Kizek R, Adam V, Hrabeta J, Eckschlager T, Smutny S, Burda JV, Frei E, Stiborová M. Anthracyclines and ellipticines as DNA-damaging anticancer drugs; recent advances. Pharmacol Ther 2012;133:26-39.
16. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984;226:466-8.
17. Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 2006;66:4863-71.
18. Cullinane C, Phillips DR. Induction of stable transcriptional blockage sites by adriamycin: GpC specificity of apparent adriamycin-DNA adducts and dependence on iron(III) ions. Biochemistry 1990;29:5638-46.
19. Wang AH, Gao YG, Liaw YC, Li YK. Formaldehyde cross-links daunorubicin and DNA efficiently: HPLC and X-ray diffraction studies. Biochemistry 1991;30:3812-5.
20. Taatjes DJ, Gaudiano G, Resing K, Koch TH. Alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J Med Chem 1996;39:4135-8.
21. Zeman SM, Phillips DR, Crothers DM. Characterization of covalent adriamycin-DNA adducts. Proc Natl Acad Sci USA 1998;95:11561-5.
22. Cutts SM, Parker BS, Swift LP, Kimura KI, Phillips DR. Structural requirements 2000;15:373-86.
23. Kato S, Burke PJ, Fenick DJ, Taatjes DJ, Bierbaum VM, Koch TH. Mass spectrometric measurement of formaldehyde generated in breast cancer cells upon treatment with anthracycline antitumor drugs. Chem Res Toxicol 2000;13:509-16.
24. Kato S, Burke PJ, Koch TH, Bierbaum VM. Formaldehyde in human cancer cells: detection by preconcentration-chemical ionization mass spectrometry. Anal Chem 2001;73:2992-7.
25. Coldwell KE, Cutts SM, Ognibene TJ, Henderson PT, Phillips DR. Detection of adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant adriamycin concentrations. Nucleic Acids Res 2008;36:e100.
26. Cutts SM, Rephaeli A, Nudelman A, Hmelnitsky I, Phillips DR. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res 2001;61:8194-202.
27. Cutts SM, Nudelman A, Rephaeli A, Phillips DR. The power and potential of doxorubicin-DNA adducts. Life. 2005;57:73-81.
28. Cutts SM, Swift LP, Pillay V, Forrest RA, Nudelman A, Rephaeli A, et al. Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate. Mol Cancer Ther 2007;6:1450-9.
29. 32P-postlabeling analysis of nonradioactive aromatic carcinogen-DNA adducts. Carcinogenesis 1982;3:1081-92.
30. 32P-postlabeling analysis of DNA adducts persisting for up to 42 weeks in the skin, epidermis and dermis of mice treated topically with 7,12-dimethylbenz[a]anthracene. Carcinogenesis 1985;6: 1117-26.
31. 32Ppostlabelling test for structurally diverse DNA adducts, Carcinogenesis 1986;7:1543-51.
32. Reddy MV, Bleicher WT, Blackburn GR, Mackerer ER. DNA adduc tion by phenol, hydroquinone, or benzoquinone in vitro but not in vivo: nuclease P1-enhanced 32P-postlabeling of adducts as labeled nucleoside bisphosphates, dinucleotides and nucleoside monophosphates. Carcinogenesis 1990;8:1349-57.
33. 2-oxide. Cancer Res 2004;64:8374-80.
34. Stiborová M, Poljaková J, Ryšlavá H, Dračíinský M, Eckschlager T, Frei E. Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine. Int J Cancer 2007;120:243-51.
35. 32P-adduct assay: comparative recoveries of structurally diverse DNA adducts in the various enhancement procedures. Carcinogenesis 1988;9:1687-93.
36. Stiborová M, Mikšanová M, Šulc M, Rýdlová H, Schmeiser HH, Frei E. Identification of a genotoxic mechanism for the carcinogenicity of the environmental pollutant and suspected human carcinogen o-anisidine. Int J Cancer 2005;116:667-78.
37. Stiborová M, Mikšanová M, Smrček S, Bieler CA, Breuer A, Klokow KA, Schmeiser HH, Frei E. Identification of a genotoxic mechanism for 2-nitroanisole carcinogenicity and of its carcinogenic potential for humans. Carcinogenesis 2004;25:833-40.
38. Huska D, Adam V, Babula P, Hrabeta J, Stiborová M, Eckschlager T, Trnkova L, Kizek R. Square wave voltametry as a tool for investigation of doxorubicin interactions with DNA isolated from neuroblastoma cells. Electroanalysis 2009;21:487-95.